Therapeutic Asset Ratings

Lorazepam

Belzutifan

Calderasib

DYNAMOS

mk-1084

Sacituzumab Tirumotecan

Benadryl

human hyaluronidase isozyme-5 (HYAL5, sperm adhesion molecule 1, SPAM1, hyaluronidase PH-20, EC:3.2.1.35) fragment (3-433, 1-431 in the current sequence) engineered variant with the structural domain replaced by the corresponding region of human hyaluronidase isozyme-1 (HYAL1)(³⁰⁶TLSIMRSMKSCLLDDNYMETI³²⁶>³⁰⁴SWENTRTKESCQAIKEYMDTT³²⁴), produced in Chinese hamster ovary (CHO) cells, cell line DG44, glycoform alfa

human hyaluronidase isozyme-5 (HYAL5, sperm adhesion molecule 1, SPAM1, hyaluronidase PH-20, EC:3.2.1.35) fragment (3-433, 1-431 in the current sequence) engineered variant with the structural domain replaced by the corresponding region of human hyaluronidase isozyme-1 (HYAL1)(³⁰⁶TLSIMRSMKSCLLDDNYMETI³²⁶>³⁰⁴SWENTRTKESCQAIKEYMDTT³²⁴), produced in Chinese hamster ovary (CHO) cells, cell line DG44, glycoform alfa

immunoglobulin G1-kappa, anti-[Homo sapiens CDH6(cadherin 6, K-cadherin (foetal kidney), cadherin 6 type 2)], humanized monoclonal antibody conjugated to deruxtecan, comprising a linker and a camptothecin derivative

Intismeran

azd6244

Cyclophosphamide

Epirubicin

mk-1084

Patritumab Deruxtecan

Pembrolizumab

Sacituzumab Tirumotecan

Homodimeric fragment crystallizable fusion protein comprised of the extracellular domain of the human transforming growth factor beta receptor type II linked to a human IgG1 Fc domain

mk-4334

Benadryl

Favezelimab

her3-dxd

I-Dxd

Ifinatamab Deruxtecan